225 related articles for article (PubMed ID: 26774055)
1. Absence of ethnic differences in the pharmacokinetics of moxifloxacin, simvastatin, and meloxicam among three East Asian populations and Caucasians.
Hasunuma T; Tohkin M; Kaniwa N; Jang IJ; Yimin C; Kaneko M; Saito Y; Takeuchi M; Watanabe H; Yamazoe Y; Uyama Y; Kawai S
Br J Clin Pharmacol; 2016 Jun; 81(6):1078-90. PubMed ID: 26774055
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and Pharmacodynamics of Meloxicam in East Asian Populations: The Role of Ethnicity on Drug Response.
Aoyama T; Ishida Y; Kaneko M; Miyamoto A; Saito Y; Tohkin M; Kawai S; Matsumoto Y
CPT Pharmacometrics Syst Pharmacol; 2017 Dec; 6(12):823-832. PubMed ID: 29024493
[TBL] [Abstract][Full Text] [Related]
3. Impact of ABCG2 and SLCO1B1 polymorphisms on pharmacokinetics of rosuvastatin, atorvastatin and simvastatin acid in Caucasian and Asian subjects: a class effect?
Birmingham BK; Bujac SR; Elsby R; Azumaya CT; Wei C; Chen Y; Mosqueda-Garcia R; Ambrose HJ
Eur J Clin Pharmacol; 2015 Mar; 71(3):341-55. PubMed ID: 25673568
[TBL] [Abstract][Full Text] [Related]
4. Simvastatin pharmacokinetics in healthy Chinese subjects and its relations with CYP2C9, CYP3A5, ABCB1, ABCG2 and SLCO1B1 polymorphisms.
Zhou Q; Ruan ZR; Jiang B; Yuan H; Zeng S
Pharmazie; 2013 Feb; 68(2):124-8. PubMed ID: 23469684
[TBL] [Abstract][Full Text] [Related]
5. Effects of CYP2C9*1/*13 on the pharmacokinetics and pharmacodynamics of meloxicam.
Bae JW; Choi CI; Jang CG; Lee SY
Br J Clin Pharmacol; 2011 Apr; 71(4):550-5. PubMed ID: 21395648
[TBL] [Abstract][Full Text] [Related]
6. Effect of CYP2C9*3 mutant variants on meloxicam pharmacokinetics in a healthy Chinese population.
Zhang M; Yang Y; Zhao G; Di X; Xu L; Jiang N; Xu J; Xu X
Genet Mol Res; 2014 Feb; 13(1):831-7. PubMed ID: 24615047
[TBL] [Abstract][Full Text] [Related]
7. Strongly increased exposure of meloxicam in CYP2C9*3/*3 individuals.
Lee HI; Bae JW; Choi CI; Lee YJ; Byeon JY; Jang CG; Lee SY
Pharmacogenet Genomics; 2014 Feb; 24(2):113-7. PubMed ID: 24322170
[TBL] [Abstract][Full Text] [Related]
8. Lack of ethnic differences of moxifloxacin and metabolite pharmacokinetics in East Asian men.
Kaneko M; Aoyama T; Ishida Y; Miyamoto A; Saito Y; Tohkin M; Kawai S; Matsumoto Y
J Pharmacokinet Pharmacodyn; 2018 Apr; 45(2):199-214. PubMed ID: 29170990
[TBL] [Abstract][Full Text] [Related]
9. Thorough QT study of the effect of oral moxifloxacin on QTc interval in the fed and fasted state in healthy Japanese and Caucasian subjects.
Taubel J; Ferber G; Lorch U; Batchvarov V; Savelieva I; Camm AJ
Br J Clin Pharmacol; 2014 Jan; 77(1):170-9. PubMed ID: 23713767
[TBL] [Abstract][Full Text] [Related]
10. Effects of statin treatments and polymorphisms in UGT1A1 and SLCO1B1 on serum bilirubin levels in Chinese patients with hypercholesterolaemia.
Hu M; Tomlinson B
Atherosclerosis; 2012 Aug; 223(2):427-32. PubMed ID: 22749334
[TBL] [Abstract][Full Text] [Related]
11. CYP2C9*3(1075A > C), ABCB1 and SLCO1B1 genetic polymorphisms and gender are determinants of inter-subject variability in pitavastatin pharmacokinetics.
Zhou Q; Chen QX; Ruan ZR; Yuan H; Xu HM; Zeng S
Pharmazie; 2013 Mar; 68(3):187-94. PubMed ID: 23556337
[TBL] [Abstract][Full Text] [Related]
12. Explaining Ethnic Variability of Transporter Substrate Pharmacokinetics in Healthy Asian and Caucasian Subjects with Allele Frequencies of OATP1B1 and BCRP: A Mechanistic Modeling Analysis.
Li R; Barton HA
Clin Pharmacokinet; 2018 Apr; 57(4):491-503. PubMed ID: 28653144
[TBL] [Abstract][Full Text] [Related]
13. Rosuvastatin pharmacokinetics and pharmacogenetics in Caucasian and Asian subjects residing in the United States.
Birmingham BK; Bujac SR; Elsby R; Azumaya CT; Zalikowski J; Chen Y; Kim K; Ambrose HJ
Eur J Clin Pharmacol; 2015 Mar; 71(3):329-40. PubMed ID: 25630984
[TBL] [Abstract][Full Text] [Related]
14. [Pharmacokinetics of meloxicam in healthy Chinese volunteers].
Xu HY; Zhong DF; Zhao LM; Zhang YF; Zhang BJ
Yao Xue Xue Bao; 2001 Jan; 36(1):71-3. PubMed ID: 12579866
[TBL] [Abstract][Full Text] [Related]
15. A quantitative enterohepatic circulation model: development and evaluation with tesofensine and meloxicam.
Lehr T; Staab A; Tillmann C; Trommeshauser D; Schaefer HG; Kloft C
Clin Pharmacokinet; 2009; 48(8):529-42. PubMed ID: 19705923
[TBL] [Abstract][Full Text] [Related]
16. Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment.
Lee E; Ryan S; Birmingham B; Zalikowski J; March R; Ambrose H; Moore R; Lee C; Chen Y; Schneck D
Clin Pharmacol Ther; 2005 Oct; 78(4):330-41. PubMed ID: 16198652
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of meloxicam in plasma and urine of horses.
Toutain PL; Reymond N; Laroute V; Garcia P; Popot MA; Bonnaire Y; Hirsch A; Narbe R
Am J Vet Res; 2004 Nov; 65(11):1542-7. PubMed ID: 15566093
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of tolbutamide in ethnic Chinese.
Gross AS; Bridge S; Shenfield GM
Br J Clin Pharmacol; 1999 Feb; 47(2):151-6. PubMed ID: 10190649
[TBL] [Abstract][Full Text] [Related]
19. Meloxicam pharmacokinetics in renal impairment.
Boulton-Jones JM; Geddes CG; Heinzel G; Türck D; Nehmiz G; Bevis PJ
Br J Clin Pharmacol; 1997 Jan; 43(1):35-40. PubMed ID: 9056050
[TBL] [Abstract][Full Text] [Related]
20. Differences in cytochrome p450-mediated pharmacokinetics between chinese and caucasian populations predicted by mechanistic physiologically based pharmacokinetic modelling.
Barter ZE; Tucker GT; Rowland-Yeo K
Clin Pharmacokinet; 2013 Dec; 52(12):1085-100. PubMed ID: 23818090
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
